News

Morphine synthesis finding paves way for new painkillers


 

FROM SCIENCE

References

Researchers have found a gene that is involved in the morphine-producing pathway of poppies.

The finding completes the biosynthetic pathway to morphine, allowing investigations of microbial-based approaches to developing opiate-based pain relievers.

By studying mutations in the poppy plant Papaver somniferum, Thilo Winzer and his colleagues at the University of York, England, discovered that the STORR enzyme, expressed by a gene of the same name, converts (S)-reticuline to an amine, known as 1,2-dehydroreticuline, and that intermediate substrate is then converted to (R)-reticuline. The STORR enzyme contains a cytochrome P450 module, which facilitates the first step of the process, along with oxidoreductase modules that facilitate the second step, according to the researchers, whose collaborators include researchers at GlaxoSmithKline in Boronia, VIC, Australia.

The discovery is one more step in recent efforts to engineer the morphine biosynthesis pathway in yeast, paving the way for cheaper ways to produce painkillers that don’t rely on cultivating poppy fields.

Click here to read the study at Science.

Recommended Reading

OARSI: Set concrete walking goals in knee OA
MDedge Rheumatology
DDW: Novel acid blocker holds its own against PPIs
MDedge Rheumatology
Amplified pain in knee osteoarthritis linked to insomnia, catastrophizing
MDedge Rheumatology
Pharmacogenomics for pain meds promising but not ready
MDedge Rheumatology
ICOO: Opioid prescribing program yields broad benefits
MDedge Rheumatology
ICOO: Quality metrics needed for medical marijuana
MDedge Rheumatology
New strategy tackles pain in refractory patients
MDedge Rheumatology
ICOO: Opioids blurring criminal activity and malpractice
MDedge Rheumatology
Arthroscopic knee surgery offers no lasting pain benefit
MDedge Rheumatology
Harnessing the placebo effect in management of osteoarthritis
MDedge Rheumatology